Login Register Cart 0
Current Cancer Drug Targets

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Translate in Chinese
Review Article

Controversial Role of Opioids: From Pain Control to Cancer Recurrence in Breast Cancer

Author(s): Mudasir Maqboolorcid of author, Gyas Khanorcid of author, Liming Zhang and Md Sadique Hussain*

Volume 25, Issue 11, 2025

Published on: 18 June, 2025

Page: [1335 - 1348] Pages: 14

DOI: 10.2174/0115680096391788250610080609

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Opioids are widely used for pain management in breast cancer patients; however, their influence on tumor progression and recurrence remains controversial. Opioid receptors-mu (MOR), delta (DOR), and kappa (KOR)-play diverse roles in cancer biology, modulating tumor growth, immune responses, and angiogenesis. MOR activation is associated with increased proliferation, Epithelial- Mesenchymal Transition (EMT), and immunosuppression, contributing to an aggressive tumor phenotype. Conversely, KOR exhibits tumor-suppressive properties, reducing angiogenesis via VEGF inhibition. Emerging preclinical evidence suggests that opioids, particularly morphine, may facilitate breast cancer progression by enhancing cancer cell migration, angiogenesis, and immune evasion. Genetic variations in opioid receptor pathways, such as the OPRM1 A118G polymorphism, further complicate the opioid-cancer relationship, demonstrating population-dependent effects on patient outcomes. In contrast, tramadol has shown potential immune-protective effects by preserving Natural Killer (NK) cell function and inhibiting adrenergic signaling; fentanyl and sufentanil exhibit variable impacts on tumor biology, necessitating further investigation. Clinical studies, however, remain inconclusive regarding opioids' direct contribution to breast cancer recurrence, highlighting the need for targeted research. Opioid-sparing analgesic strategies, including multimodal pain management, regional anesthesia, and immunomodulatory agents, offer promising alternatives to mitigate potential oncogenic risks while ensuring adequate pain relief. Future studies integrating single-cell transcriptomics and tumor microenvironment analyses will be critical in elucidating the molecular impact of opioids in breast cancer. Personalized pain management approaches tailored to genetic and clinical profiles may optimize oncological outcomes while preserving analgesic efficacy.

Keywords: Breast cancer, immunosuppression, morphine, opioid analgesics, pain management, tramadol, tumor microenvironment, tumor progression.

Next »

Graphical Abstract

Graphical abstract illustrating key findings of the study

[1]
Sun, D.; Li, X.; Nie, S.; Liu, J.; Wang, S. Disorders of cancer metabolism: The therapeutic potential of cannabinoids. Biomed. Pharmacother., 2023, 157, 113993.
[http://dx.doi.org/10.1016/j.biopha.2022.113993] [PMID: 36379120]
[2]
Li, R.; Luo, P.; Guo, Y.; He, Y.; Wang, C. Clinical features, treatment, and prognosis of SGLT2 inhibitors induced acute pancreatitis. Expert Opin. Drug Saf., 2024, 1-5.
[http://dx.doi.org/10.1080/14740338.2024.2396387] [PMID: 39172128]
[3]
Zeng, Q.; Chen, C.; Chen, C.; Song, H.; Li, M.; Yan, J.; Lv, X. Serum Raman spectroscopy combined with convolutional neural network for rapid diagnosis of HER2-positive and triple-negative breast cancer. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2023, 286, 122000.
[http://dx.doi.org/10.1016/j.saa.2022.122000] [PMID: 36279798]
[4]
Bennett, M.; Paice, J.A.; Wallace, M. Pain and opioids in cancer care: Benefits, risks, and alternatives. Am. Soc. Clin. Oncol. Educ. Book, 2017, 37, 705-713.
[http://dx.doi.org/10.1200/EDBK_180469] [PMID: 28561731]
[5]
Patrad, E.; Khalighfard, S.; Khori, V.; Alizadeh, A.M. The other side of the coin: Positive view on the role of opioids in cancer. Eur. J. Pharmacol., 2022, 923, 174888.
[http://dx.doi.org/10.1016/j.ejphar.2022.174888] [PMID: 35367422]
[6]
Cao, Z.; Zhu, J.; Wang, Z.; Peng, Y.; Zeng, L. Comprehensive pan-cancer analysis reveals ENC1 as a promising prognostic biomarker for tumor microenvironment and therapeutic responses. Sci. Rep., 2024, 14(1), 25331.
[http://dx.doi.org/10.1038/s41598-024-76798-9] [PMID: 39455818]
[7]
Meng, H.; Dai, T.; Hanlon, J.G.; Downar, J.; Alibhai, S.M.H.; Clarke, H. Cannabis and cannabinoids in cancer pain management. Curr. Opin. Support. Palliat. Care, 2020, 14(2), 87-93.
[http://dx.doi.org/10.1097/SPC.0000000000000493] [PMID: 32332209]
[8]
Khan, Y.; Rizvi, S.; Raza, A.; Khan, A.; Hussain, S.; Khan, N.U.; Alshammari, S.O.; Alshammari, Q.A.; Alshammari, A.; Ellakwa, D.E.S. Tailored therapies for triple-negative breast cancer: Current landscape and future perceptions. Naunyn Schmiedebergs Arch. Pharmacol., 2025.
[http://dx.doi.org/10.1007/s00210-025-03896-4] [PMID: 40029385]
[9]
Novy, D.M.; Nelson, D.V.; Koyyalagunta, D.; Cata, J.P.; Gupta, P.; Gupta, K. Pain, opioid therapy, and survival: A needed discussion. Pain, 2020, 161(3), 496-501.
[http://dx.doi.org/10.1097/j.pain.0000000000001736] [PMID: 31693537]
[10]
Zhou, Q.; Zhang, Z.; Long, S.; Li, W.; Wang, B.; Liang, N. Opioids in cancer: The κ opioid receptor (Review). Mol. Med. Rep., 2022, 25(2), 25.
[http://dx.doi.org/10.3892/mmr.2021.12560] [PMID: 34878160]
[11]
Bhoir, S.; Uhelski, M.; Guerra-Londono, J.J.; Cata, J.P. The role of opioid receptors in cancer. Adv. Biol., 2023, 7(7), 2300102.
[http://dx.doi.org/10.1002/adbi.202300102] [PMID: 37132160]
[12]
Zhu, L.; Bai, M.; Xiao, S.; Liu, Y.; Zhu, Q.; Wang, Z.; Zhao, J.; Zhang, W.; Chen, D. In-situ monitoring of cellular H2O2 within 3D cell clusters using conductive scaffolds. Talanta, 2024, 279, 126559.
[http://dx.doi.org/10.1016/j.talanta.2024.126559] [PMID: 39018950]
[13]
Santoni, A.; Santoni, M.; Arcuri, E. Chronic cancer pain: Opioids within tumor microenvironment affect neuroinflammation, tumor and pain evolution. Cancers, 2022, 14(9), 2253.
[http://dx.doi.org/10.3390/cancers14092253] [PMID: 35565382]
[14]
Hussain, M.S.; Majami, A.A.; Ali, H.; Gupta, G.; Almalki, W.H.; Alzarea, S.I.; Kazmi, I.; Syed, R.U.; Khalifa, N.E.; Bin Break, M.K.; Khan, R.; Altwaijry, N.; Sharma, R. The complex role of MEG3: An emerging long non-coding RNA in breast cancer. Pathol. Res. Pract., 2023, 251, 154850.
[http://dx.doi.org/10.1016/j.prp.2023.154850] [PMID: 37839358]
[15]
Plein, L.M.; Rittner, H.L. Opioids and the immune system – Friend or foe. Br. J. Pharmacol., 2018, 175(14), 2717-2725.
[http://dx.doi.org/10.1111/bph.13750] [PMID: 28213891]
[16]
Wang, R.; Zhang, Y.; Shan, F. Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy. Int. Immunopharmacol., 2019, 75, 105785.
[http://dx.doi.org/10.1016/j.intimp.2019.105785] [PMID: 31404891]
[17]
Lennon, F.E.; Moss, J.; Singleton, P.A.; Riou, B. The μ-opioid receptor in cancer progression: Is there a direct effect? Anesthesiology, 2012, 116(4), 940-945.
[http://dx.doi.org/10.1097/ALN.0b013e31824b9512] [PMID: 22357347]
[18]
Waldhoer, M.; Bartlett, S.E.; Whistler, J.L. Opioid Receptors. Annu. Rev. Biochem., 2004, 73(1), 953-990.
[http://dx.doi.org/10.1146/annurev.biochem.73.011303.073940] [PMID: 15189164]
[19]
Shang, Y.; Filizola, M. Opioid receptors: Structural and mechanistic insights into pharmacology and signaling. Eur J. Pharmacol., 2015, 763(Pt B), 206-213.
[http://dx.doi.org/10.1016/j.ejphar.2015.05.012] [PMID: 25981301]
[20]
Zhao, C.; Song, W.; Wang, J.; Tang, X.; Jiang, Z. Immunoadjuvant-functionalized metal-organic frameworks: Synthesis and applications in tumor immune modulation. Chem. Commun., 2025, 61, 1962-1977.
[http://dx.doi.org/10.1039/D4CC06510G]
[21]
Ma, X.; Cheng, H.; Hou, J.; Jia, Z.; Wu, G.; Lü, X.; Li, H.; Zheng, X.; Chen, C. Detection of breast cancer based on novel porous silicon Bragg reflector surface-enhanced Raman spectroscopy-active structure. Chin. Opt. Lett., 2020, 18(5), 051701.
[http://dx.doi.org/10.3788/COL202018.051701]
[22]
Chapman, C.R.; Lipschitz, D.L.; Angst, M.S.; Chou, R.; Denisco, R.C.; Donaldson, G.W.; Fine, P.G.; Foley, K.M.; Gallagher, R.M.; Gilson, A.M.; Haddox, J.D.; Horn, S.D.; Inturrisi, C.E.; Jick, S.S.; Lipman, A.G.; Loeser, J.D.; Noble, M.; Porter, L.; Rowbotham, M.C.; Schoelles, K.M.; Turk, D.C.; Volinn, E.; Von Korff, M.R.; Webster, L.R.; Weisner, C.M. Opioid pharmacotherapy for chronic non-cancer pain in the United States: A research guideline for developing an evidence-base. J. Pain, 2010, 11(9), 807-829.
[http://dx.doi.org/10.1016/j.jpain.2010.02.019] [PMID: 20430701]
[23]
Sah, D.; Shoffel-Havakuk, H.; Tsur, N.; Uhelski, M.L.; Gottumukkala, V.; Cata, J.P. Opioids and cancer: Current understanding and clinical considerations. Curr. Oncol., 2024, 31(6), 3086-3098.
[http://dx.doi.org/10.3390/curroncol31060235] [PMID: 38920719]
[24]
Gopalakrishnan, L.; Chatterjee, O.; Ravishankar, N.; Suresh, S.; Raju, R.; Mahadevan, A.; Prasad, T.S.K. Opioid receptors signaling network. J. Cell Commun. Signal., 2022, 16(3), 475-483.
[http://dx.doi.org/10.1007/s12079-021-00653-z] [PMID: 34724150]
[25]
Scroope, C.A.; Singleton, Z.; Hollmann, M.W.; Parat, M.O. Opioid receptor-mediated and non-opioid receptor-mediated roles of opioids in tumour growth and metastasis. Front. Oncol., 2021, 11, 792290.
[http://dx.doi.org/10.3389/fonc.2021.792290] [PMID: 35004315]
[26]
Wang, R.; Li, S.; Wang, B.; Wang, G.; Zheng, H. Impact of opioids and mu-opioid receptors on oncologic metastasis. Am. J. Cancer Res., 2024, 14(9), 4236-4247.
[http://dx.doi.org/10.62347/SCLS3277] [PMID: 39417177]
[27]
Tregubenko, P.; Zvonarev, V. Impact of opioid use in hematological malignancies: Clinical, immunological and concomitant aspects. J. Hematol., 2020, 9(3), 41-54.
[http://dx.doi.org/10.14740/jh689] [PMID: 32855752]
[28]
Dong, Q.; Jiang, Z. Platinum–iron nanoparticles for oxygen-enhanced sonodynamic tumor cell suppression. Inorganics, 2024, 12(12), 331.
[http://dx.doi.org/10.3390/inorganics12120331]
[29]
Nagata, K.; Nagase, H.; Okuzumi, A.; Nishiyama, C. Delta opioid receptor agonists ameliorate colonic inflammation by modulating immune responses. Front. Immunol., 2021, 12, 730706.
[http://dx.doi.org/10.3389/fimmu.2021.730706] [PMID: 34630408]
[30]
Goode-Romero, G.; Dominguez, L. Descriptive molecular pharmacology of the δ opioid receptor (DOR): A computational study with structural approach. PLoS One, 2024, 19(7), e0304068.
[http://dx.doi.org/10.1371/journal.pone.0304068] [PMID: 38991032]
[31]
Lyu, Z.; Xin, M.; Oyston, D.R.; Xue, T.; Kang, H.; Wang, X.; Wang, Z.; Li, Q. Cause and consequence of heterogeneity in human mesenchymal stem cells: Challenges in clinical application. Pathol. Res. Pract., 2024, 260, 155354.
[http://dx.doi.org/10.1016/j.prp.2024.155354] [PMID: 38870711]
[32]
Dalefield, M.L.; Scouller, B.; Bibi, R.; Kivell, B.M. The kappa opioid receptor: A promising therapeutic target for multiple pathologies. Front. Pharmacol., 2022, 13, 837671.
[http://dx.doi.org/10.3389/fphar.2022.837671] [PMID: 35795569]
[33]
Singleton, P.A.; Mirzapoiazova, T.; Hasina, R.; Salgia, R.; Moss, J. Increased μ-opioid receptor expression in metastatic lung cancer. Br J. Anaesth, 2014, 113(Suppl 1), i103-i108. (Suppl. 1)
[http://dx.doi.org/10.1093/bja/aeu165] [PMID: 24920011]
[34]
Lahav, Y.; Cohen, O.; Huszar, M.; Levy, I.; Cata, J.P.; Halperin, D. Mu-Opioid receptor expression in laryngeal cancer. J. Voice, 2023, 37(3), 433-439.
[http://dx.doi.org/10.1016/j.jvoice.2021.02.018] [PMID: 33750623]
[35]
Zhang, H.; Sun, M.; Zhou, D.; Gorur, A.; Sun, Z.; Zeng, W.; Cata, J.P.; Chen, W.; Miao, C. Increased mu-opioid receptor expression is associated with reduced disease-free and overall survival in laryngeal squamous cell carcinoma. Br. J. Anaesth., 2020, 125(5), 722-729.
[http://dx.doi.org/10.1016/j.bja.2020.07.051] [PMID: 32900505]
[36]
Mathew, B.; Lennon, F.E.; Siegler, J.; Mirzapoiazova, T.; Mambetsariev, N.; Sammani, S.; Gerhold, L.M.; LaRiviere, P.J.; Chen, C.T.; Garcia, J.G.; Salgia, R.; Moss, J.; Singleton, P.A. The novel role of the mu opioid receptor in lung cancer progression: A laboratory investigation. Anesth. Analg., 2011, 112(3), 558-567.
[http://dx.doi.org/10.1213/ANE.0b013e31820568af] [PMID: 21156980]
[37]
Zylla, D.; Gourley, B.L.; Vang, D.; Jackson, S.; Boatman, S.; Lindgren, B.; Kuskowski, M.A.; Le, C.; Gupta, K.; Gupta, P. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer, 2013, 119(23), 4103-4110.
[http://dx.doi.org/10.1002/cncr.28345] [PMID: 24104703]
[38]
Zhang, H.; Qu, M.; Gorur, A.; Sun, Z.; Cata, J.P.; Chen, W.; Miao, C. Association of Mu-Opioid Receptor(MOR) expression and opioids requirement with survival in patients with stage I-III pancreatic ductal adenocarcinoma. Front. Oncol., 2021, 11, 686877.
[http://dx.doi.org/10.3389/fonc.2021.686877] [PMID: 34222012]
[39]
de Sousa, A.; Dantas, T.; Barros Silva, P.; Martins, C.; Freire, G.; Junior, H.; Brito, G.A.; Pereira, K.; Leitão, R.F. Analysis of the immunoexpression of opioid receptors and their correlation with markers of angiogenesis, cell proliferation and apoptosis in breast cancer. Asian Pac. J. Cancer Prev., 2021, 22(2), 633-640.
[http://dx.doi.org/10.31557/APJCP.2021.22.2.633] [PMID: 33639684]
[40]
Schreiber, G.; Campa, M.J.; Prabhakar, S.; O’Briant, K.; Bepler, G.; Patz, E.F. Molecular characterization of the human delta opioid receptor in lung cancer. Anticancer Res., 1998, 18(3A), 1787-1792.
[PMID: 9673405]
[41]
Wei, Y.C.; Zhang, B.; Li, X.; Liu, X.M.; Zhang, J.; Lei, B.; Li, B.; Zhai, R.; Chen, Q.; Li, Y. Upregulation and activation of δ-opioid receptors promotes the progression of human breast cancer. Oncol. Rep., 2016, 36(5), 2579-2586.
[http://dx.doi.org/10.3892/or.2016.5109] [PMID: 27665747]
[42]
Campa, M.J.; Schreiber, G.; Bepler, G.; Bishop, M.J.; McNutt, R.W.; Chang, K.J.; Patz, E.F. Characterization of delta opioid receptors in lung cancer using a novel nonpeptidic ligand. Cancer Res., 1996, 56(7), 1695-1701.
[PMID: 8603422]
[43]
Madar, I.; Bencherif, B.; Lever, J.; Heitmiller, R.F.; Yang, S.C. Brock, M Imaging delta- and mu-opioid receptors by PET in lung carcinoma patients. J. Nucl. Med., 2007, 48(2), 207-213.
[PMID: 17268016]
[44]
Montagna, G.; Gupta, H.V.; Hannum, M.; Tan, K.S.; Lee, J.; Scarpa, J.R.; Plitas, G.; Irie, T.; McCormick, P.J.; Fischer, G.W.; Morrow, M.; Mincer, J.S. Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer. Br. J. Anaesth., 2021, 126(2), 367-376.
[http://dx.doi.org/10.1016/j.bja.2020.10.021] [PMID: 33220939]
[45]
Wang, H.; Hao, R.; Liu, W.; Zhang, Y.; Ma, S.; Lu, Y.; Hu, J.; Qi, Y. Identification of transcription factors associated with the disease-free survival of triple-negative breast cancer through weighted gene co-expression network analysis. Cytojournal, 2024, 21, 71.
[http://dx.doi.org/10.25259/Cytojournal_127_2024] [PMID: 39917004]
[46]
Zhang, Y.F.; Xu, Q.X.; Liao, L.D.; Xu, X.E.; Wu, J.Y.; Shen, J.; Wu, Z.Y.; Shen, J.H.; Li, E.M.; Xu, L.Y. κ-Opioid receptor in the nucleus is a novel prognostic factor of esophageal squamous cell carcinoma. Hum. Pathol., 2013, 44(9), 1756-1765.
[http://dx.doi.org/10.1016/j.humpath.2012.11.025] [PMID: 23574786]
[47]
Zagon, I.; McLaughlin, P. Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers. Int. J. Oncol., 2006, 29(2), 489-494.
[http://dx.doi.org/10.3892/ijo.29.2.489] [PMID: 16820893]
[48]
Bimonte, S.; Barbieri, A.; Rea, D.; Palma, G.; Luciano, A.; Cuomo, A.; Arra, C.; Izzo, F. Morphine promotes tumor angiogenesis and increases breast cancer progression. BioMed Res. Int., 2015, 2015, 1-8.
[http://dx.doi.org/10.1155/2015/161508] [PMID: 26064880]
[49]
Ecimovic, P.; Murray, D.; Doran, P.; McDonald, J.; Lambert, D.G.; Buggy, D.J. Direct effect of morphine on breast cancer cell function in vitro: Role of the NET1 gene. Br. J. Anaesth., 2011, 107(6), 916-923.
[http://dx.doi.org/10.1093/bja/aer259] [PMID: 21857017]
[50]
Gupta, K.; Kshirsagar, S.; Chang, L.; Schwartz, R.; Law, P.Y.; Yee, D.; Hebbel, R.P. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res., 2002, 62(15), 4491-4498.
[PMID: 12154060]
[51]
Guo, Z.; Guan, K.; Bao, M.; He, B.; Lu, J. LINC-PINT plays an anti-tumor role in nasopharyngeal carcinoma by binding to XRCC6 and affecting its function. Pathol. Res. Pract., 2024, 260, 155460.
[http://dx.doi.org/10.1016/j.prp.2024.155460] [PMID: 39032384]
[52]
Jiang, C.H.; Sun, T.L.; Xiang, D.X.; Wei, S.S.; Li, W.Q. Anticancer activity and mechanism of xanthohumol: A prenylated flavonoid from hops (Humulus lupulus L.). Front. Pharmacol., 2018, 9, 530.
[http://dx.doi.org/10.3389/fphar.2018.00530] [PMID: 29872398]
[53]
Li, Y.; Li, G.; Tao, T.; Kang, X.; Liu, C.; Zhang, X.; Wang, C.; Li, C.; Guo, X. The μ-opioid receptor (MOR) promotes tumor initiation in hepatocellular carcinoma. Cancer Lett., 2019, 453, 1-9.
[http://dx.doi.org/10.1016/j.canlet.2019.03.038] [PMID: 30928385]
[54]
Lu, H.; Zhang, H.; Weng, M.; Zhang, J.; Jiang, N.; Cata, J.P.; Ma, D.; Chen, W.K.; Miao, C.H. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer. J. Cell. Physiol., 2021, 236(6), 4445-4454.
[http://dx.doi.org/10.1002/jcp.30161] [PMID: 33184860]
[55]
Tagirasa, R.; Yoo, E. Role of serine proteases at the tumor-stroma interface. Front. Immunol., 2022, 13, 832418.
[http://dx.doi.org/10.3389/fimmu.2022.832418] [PMID: 35222418]
[56]
Gonzalez-Nunez, V.; Noriega-Prieto, J.A.; Rodríguez, R.E. Morphine modulates cell proliferation through mir133b & mir128 in the neuroblastoma SH-SY5Y cell line. Biochim. Biophys. Acta Mol. Basis Dis., 2014, 1842(4), 566-572.
[http://dx.doi.org/10.1016/j.bbadis.2014.01.003] [PMID: 24440526]
[57]
Lennon, F.E.; Mirzapoiazova, T.; Mambetsariev, B.; Poroyko, V.A.; Salgia, R.; Moss, J.; Singleton, P.A. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One, 2014, 9(3), e91577.
[http://dx.doi.org/10.1371/journal.pone.0091577] [PMID: 24662916]
[58]
Nie, Y.; Li, D.; Peng, Y.; Wang, S.; Hu, S.; Liu, M.; Ding, J.; Zhou, W. Metal organic framework coated MnO2 nanosheets delivering doxorubicin and self-activated DNAzyme for chemo-gene combinatorial treatment of cancer. Int. J. Pharm., 2020, 585, 119513.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119513] [PMID: 32526334]
[59]
Nguyen, J.; Luk, K.; Vang, D.; Soto, W.; Vincent, L.; Robiner, S.; Saavedra, R.; Li, Y.; Gupta, P.; Gupta, K. Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer. Br J. Anaesth, 2014, 113(Suppl 1), i4-i13. Suppl. 1
[http://dx.doi.org/10.1093/bja/aeu090] [PMID: 24861561]
[60]
Lennon, F.E.; Mirzapoiazova, T.; Mambetsariev, B.; Salgia, R.; Moss, J.; Singleton, P.A. Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology, 2012, 116(4), 857-867.
[http://dx.doi.org/10.1097/ALN.0b013e31824babe2] [PMID: 22343475]
[61]
Gach, K.; Szemraj, J.; Wyrębska, A.; Janecka, A. The influence of opioids on matrix metalloproteinase-2 and -9 secretion and mRNA levels in MCF-7 breast cancer cell line. Mol. Biol. Rep., 2011, 38(2), 1231-1236.
[http://dx.doi.org/10.1007/s11033-010-0222-z] [PMID: 20563853]
[62]
Hu, M.; Yuan, X.; Liu, Y.; Tang, S.; Miao, J.; Zhou, Q. Il-1β-induced NF-κB activation down-regulates miR-506 expression to promotes osteosarcoma cell growth through JAG1. Biomed. Pharmacother., 2017, 95, 1147-1155.
[http://dx.doi.org/10.1016/j.biopha.2017.08.120] [PMID: 28926924]
[63]
Xie, N.; Khabbazi, S.; Nassar, Z.D.; Gregory, K.; Vithanage, T.; Anand-Apte, B.; Cabot, P.J.; Sturgess, D.; Shaw, P.N.; Parat, M.O. Morphine alters the circulating proteolytic profile in mice: Functional consequences on cellular migration and invasion. FASEB J., 2017, 31(12), 5208-5216.
[http://dx.doi.org/10.1096/fj.201700546R] [PMID: 28784632]
[64]
Li, N.L.; Yu, B.L.; Tseng, S.C.; Hsu, C.C.; Lai, W.J.; Hsieh, P.F.; Peng, W.L.; Chen, C.M. The effect on improvement of recovery and pain scores of paravertebral block immediately before breast surgery. Acta Anaesthesiol. Taiwan., 2011, 49(3), 91-95.
[http://dx.doi.org/10.1016/j.aat.2011.08.006] [PMID: 21982169]
[65]
Gaspani, L.; Bianchi, M.; Limiroli, E.; Panerai, A.E.; Sacerdote, P. The analgesic drug tramadol prevents the effect of surgery on natural killer cell activity and metastatic colonization in rats. J. Neuroimmunol., 2002, 129(1-2), 18-24.
[http://dx.doi.org/10.1016/s0165-5728(02)00165-0] [PMID: 12161016]
[66]
Sacerdote, P.; Bianchi, M.; Gaspani, L.; Manfredi, B.; Maucione, A.; Terno, G.; Ammatuna, M.; Panerai, A.E. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth. Analg., 2000, 90(6), 1411-1414.
[http://dx.doi.org/10.1097/00000539-200006000-00028] [PMID: 10825330]
[67]
Barakat, A. Revisiting tramadol: A multi-modal agent for pain management. CNS Drugs, 2019, 33(5), 481-501.
[http://dx.doi.org/10.1007/s40263-019-00623-5] [PMID: 31004280]
[68]
Xia, M.; Tong, J.H.; Zhou, Z.Q.; Duan, M.L.; Xu, J.G.; Zeng, H.J.; Wang, S.H. Tramadol inhibits proliferation, migration and invasion via α2-adrenoceptor signaling in breast cancer cells. Eur. Rev. Med. Pharmacol. Sci., 2016, 20(1), 157-165.
[PMID: 26813469]
[69]
Yadav, P.; Ahuja, S.; Zaheer, S.; Singh, M.; Chintamani, C. Efficacy of intraoperative imprint cytology of sentinel lymph node in breast cancer. Cytojournal, 2024, 21, 4.
[http://dx.doi.org/10.25259/Cytojournal_37_2023] [PMID: 38343762]
[70]
Li, Y.; Sun, L.; Zhou, Q.; Lee, A.J.; Wang, L.; Zhang, R. Effects of opioid drugs on immune function in cancer patients. Biomed. Pharmacother., 2024, 175, 116665.
[http://dx.doi.org/10.1016/j.biopha.2024.116665] [PMID: 38701564]
[71]
Kim, M.H.; Oh, J.E.; Park, S.; Kim, J.H.; Lee, K.Y.; Bai, S.J.; Song, H.; Hwang, H.J.; Kim, D.W.; Yoo, Y.C. Tramadol use is associated with enhanced postoperative outcomes in breast cancer patients: A retrospective clinical study with in vitro confirmation. Br. J. Anaesth., 2019, 123(6), 865-876.
[http://dx.doi.org/10.1016/j.bja.2019.09.004] [PMID: 31591020]
[72]
Kocak, N.; Ozen, F.; Yildirim, I.H.; Duran, Y. Fentanyl inhibits tumorigenesis from human breast stem cells by inducing apoptosis. APJCP, 2017, 18(3), 735-739.
[http://dx.doi.org/10.22034/APJCP.2017.18.3.735] [PMID: 28441707]
[73]
Gong, L.; Qin, Q.; Zhou, L.; Ouyang, W.; Li, Y.; Wu, Y.; Li, Y. Effects of fentanyl anesthesia and sufentanil anesthesia on regulatory T cells frequencies. Int. J. Clin. Exp. Pathol., 2014, 7(11), 7708-7716.
[PMID: 25550807]
[74]
Cronin-Fenton, D.P.; Heide-Jørgensen, U.; Ahern, T.P.; Lash, T.L.; Christiansen, P.M.; Ejlertsen, B.; Sjøgren, P.; Kehlet, H.; Sørensen, H.T. Opioids and breast cancer recurrence: A Danish population-based cohort study. Cancer, 2015, 121(19), 3507-3514.
[http://dx.doi.org/10.1002/cncr.29532] [PMID: 26207518]
[75]
Joliat, G.R.; Kobayashi, K.; Hasegawa, K.; Thomson, J.E.; Padbury, R.; Scott, M.; Brustia, R.; Scatton, O.; Tran Cao, H.S.; Vauthey, J.N.; Dincler, S.; Clavien, P.A.; Wigmore, S.J.; Demartines, N.; Melloul, E. Guidelines for perioperative care for liver surgery: Enhanced recovery after surgery (ERAS) society recommendations 2022. world j surg, 2023, 47(1), 11-34.
[http://dx.doi.org/10.1007/s00268-022-06732-5] [PMID: 36310325]
[76]
Kim, R. Anesthetic technique for cancer surgery: Harm or benefit for cancer recurrence? Eur. J. Surg. Oncol., 2018, 44(5), 557-558.
[http://dx.doi.org/10.1016/j.ejso.2018.02.207] [PMID: 29530344]
[77]
Ramirez, M.F.; Cata, J.P. Anesthesia techniques and long-term oncological outcomes. Front. Oncol., 2021, 11, 788918.
[http://dx.doi.org/10.3389/fonc.2021.788918] [PMID: 34956903]
[78]
Hussain, M.S.; Agrawal, M.; Shaikh, N.K.; Saraswat, N.; Bahl, G.; Maqbool Bhat, M.; Khurana, N.; Bisht, A.S.; Tufail, M.; Kumar, R. Beyond the genome: Deciphering the role of MALAT1 in breast cancer progression. Curr. Genomics, 2024, 25(5), 343-357.
[http://dx.doi.org/10.2174/0113892029305656240503045154] [PMID: 39323624]
[79]
Tufail, M.; Wu, C.; Hussain, M.S. Dietary, addictive and habitual factors, and risk of colorectal cancer. Nutrition, 2024, 120, 112334.
[http://dx.doi.org/10.1016/j.nut.2023.112334] [PMID: 38271761]
[80]
Jayachandran, P.; Battaglin, F.; Strelez, C.; Lenz, A.; Algaze, S.; Soni, S.; Lo, J.H.; Yang, Y.; Millstein, J.; Zhang, W.; Shih, J.C.; Lu, J.; Mumenthaler, S.M.; Spicer, D.; Neman, J.; Roussos Torres, E.T.; Lenz, H.J. Breast cancer and neurotransmitters: Emerging insights on mechanisms and therapeutic directions. Oncogene, 2023, 42(9), 627-637.
[http://dx.doi.org/10.1038/s41388-022-02584-4] [PMID: 36650218]
[81]
Sánchez, M.L.; Rodríguez, F.D.; Coveñas, R. Involvement of the opioid peptide family in cancer progression. Biomedicines, 2023, 11(7), 11.
[http://dx.doi.org/10.3390/biomedicines11071993] [PMID: 37509632]
[82]
Suter, R.; Marcum, J.A. The molecular genetics of breast cancer and targeted therapy. Biologics, 2007, 1(3), 241-258.
[PMID: 19707334]
[83]
Lucia, M.; Luca, T.; Federica, D.P.; Cecilia, G.; Chiara, M.; Laura, D.M.; Carlo, D.R.; Grazia, P.M. Opioids and breast cancer recurrence: A systematic review. Cancers, 2021, 13(21), 5499.
[http://dx.doi.org/10.3390/cancers13215499] [PMID: 34771662]
[84]
Lee, Y.J.; Oh, C.S.; Choi, J.M.; Park, S.; Kim, S.H. mu-Opioid receptor polymorphisms and breast cancer recurrence in adult Korean women undergoing breast cancer surgery: A retrospective study. Int. J. Med. Sci., 2020, 17(18), 2941-2946.
[http://dx.doi.org/10.7150/ijms.49297] [PMID: 33173414]
[85]
Bortsov, A.V.; Millikan, R.C.; Belfer, I.; Boortz-Marx, R.L.; Arora, H.; McLean, S.A. μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology, 2012, 116(4), 896-902.
[http://dx.doi.org/10.1097/ALN.0b013e31824b96a1] [PMID: 22433205]
[86]
Cata, J.P.; Bugada, D.; Marchesini, M.; De Gregori, M.; Allegri, M. Opioids and cancer recurrence: A brief review of the literature. Cancer Cell Microenviron., 2016, 3, e1159.
[87]
Cruceriu, D.; Baldasici, O.; Balacescu, O.; Berindan-Neagoe, I. The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: Molecular insights and therapeutic approaches. Cell. Oncol., 2020, 43(1), 1-18.
[http://dx.doi.org/10.1007/s13402-019-00489-1] [PMID: 31900901]
[88]
Habanjar, O.; Bingula, R.; Decombat, C.; Diab-Assaf, M.; Caldefie-Chezet, F.; Delort, L. Crosstalk of inflammatory cytokines within the breast tumor microenvironment. Int. J. Mol. Sci., 2023, 24(4), 24.
[http://dx.doi.org/10.3390/ijms24044002] [PMID: 36835413]
[89]
Feng, C.; Wang, Y.; Xu, J.; Zheng, Y.; Zhou, W.; Wang, Y.; Luo, C. Precisely tailoring molecular structure of doxorubicin prodrugs to enable stable nanoassembly, rapid activation, and potent antitumor effect. Pharmaceutics, 2024, 16(12), 16.
[http://dx.doi.org/10.3390/pharmaceutics16121582] [PMID: 39771561]
[90]
Inchingolo, A.M.; Dipalma, G.; Inchingolo, A.D.; Palumbo, I.; Guglielmo, M.; Morolla, R.; Mancini, A.; Inchingolo, F. Advancing postoperative pain management in oral cancer patients: A systematic review. Pharmaceuticals, 2024, 17(4), 17.
[http://dx.doi.org/10.3390/ph17040542] [PMID: 38675500]
[91]
Sun, D.Y.; Hu, Y.J.; Li, X.; Peng, J.; Dai, Z.J.; Wang, S. Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies. Int. Immunopharmacol., 2025, 144, 113392.
[http://dx.doi.org/10.1016/j.intimp.2024.113392] [PMID: 39608170]
[92]
Xuan, W.; Hankin, J.; Zhao, H.; Yao, S.; Ma, D. The potential benefits of the use of regional anesthesia in cancer patients. Int. J. Cancer, 2015, 137(12), 2774-2784.
[http://dx.doi.org/10.1002/ijc.29306] [PMID: 25359704]
[93]
Sessler, D.I.; Pei, L.; Huang, Y.; Fleischmann, E.; Marhofer, P.; Kurz, A.; Mayers, D.B.; Meyer-Treschan, T.A.; Grady, M.; Tan, E.Y.; Ayad, S.; Mascha, E.J.; Buggy, D.J. Recurrence of breast cancer after regional or general anaesthesia: A randomised controlled trial. Lancet, 2019, 394(10211), 1807-1815.
[http://dx.doi.org/10.1016/S0140-6736(19)32313-X] [PMID: 31645288]
[94]
Ostović, H.; Šimac, B.; Pražetina, M.; Bradić, N.; Peršec, J. The Effect of Intravenous Lidocaine, Ketamine, and Lidocaine-Ketamine Combination in Colorectal Cancer Surgery: A Randomized Controlled Trial. Anesth. Analg., 2025, 140(1), 67-76.
[http://dx.doi.org/10.1213/ANE.0000000000006555] [PMID: 37224065]
[95]
Sebastian, A.; Hum, N.R.; Martin, K.A.; Gilmore, S.F.; Peran, I.; Byers, S.W.; Wheeler, E.K.; Coleman, M.A.; Loots, G.G. Single-Cell Transcriptomic Analysis of Tumor-Derived Fibroblasts and Normal Tissue-Resident Fibroblasts Reveals Fibroblast Heterogeneity in Breast Cancer. Cancers, 2020, 12(5), 12.
[PMID: 32455670]

Rights & Permissions Print Cite
Article Metrics
Pdf icon 41
Html icon 1
Find your institution